New Delhi, Aug 17 (PTI) Glenmark Pharmaceuticals Ltd on Thursday said it has received approval from the US health regulator for its generic Tacrolimus ointment indicated for the treatment of moderate to severe atopic dermatitis.

The approval granted by the US Food & Drug Administration (USFDA) is for Tacrolimus ointment, 0.03 per cent, the generic version of Protopic Ointment, 0.03 per cent of Leo Pharma AS, the company said in a statement.

Also Read | Fake Mobile Applications: IRCTC Sounds Alarm Over Malicious 'IRCTC Rail Connect' Mobile App To Trick Common Citizens.

Glenmark's Tacrolimus ointment, 0.03 per cent, will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, it added.

The Protopic Ointment, 0.03 per cent market (brand and all available therapeutic equivalents), achieved annual sales of approximately USD 15.4 million, the company said citing IQVIA sales data for the 12-month period ending June 2023.

Also Read | DRDO ADA Recruitment 2023: Vacancies Notified for 50 Project Engineer Posts, Apply Online at ada.gov.in.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)